---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-067767"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:45:14.518191+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Journey Medical expands Emrosi payer coverage to 65% of commercial lives from 29% in May 2025

## Summary
- Emrosi now has pharmacy benefit coverage for 65% of 187 million U.S. commercial lives, up from 29% in May 2025.
- Expanded coverage expected to drive further growth in total prescription demand for rosacea treatment.
- CEO cites targeted contracting strategy, increasing prescription demand, and superior clinical data as drivers.
- Emrosi is available by prescription at specialty pharmacy chains.

## SEC filing metadata
- accession: 0001104659-25-067767
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925067767/0001104659-25-067767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925067767/tm2520913d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-067767
- JSON: https://secwatch.observer/filing/0001104659-25-067767.json
- Plain text: https://secwatch.observer/filing/0001104659-25-067767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.